Document:

EXHIBIT 10.7

                        AMENDMENT TO EMPLOYMENT AGREEMENT

THIS AMENDMENT is entered into as of this 7 day of December, 2005, by and
between Oriens Life Sciences (Israel) Ltd., a private company duly registered in
Israel (the "Company"), and Dr. Shay Goldstein (the "Executive").

WHEREAS the Executive currently serves in the role of Chief Executive Officer of
the Company, pursuant to an Employment Agreement dated May 31, 2005 (the
"Agreement"; all capitalized terms used and not otherwise defined herein shall
have the meaning ascribed to them in the Agreement); and

WHEREAS the Company and the Executive both wish to continue the Executive's
employment with the Company, in the position of Chief Medical Officer ("CMO") of
the Company, under the terms and conditions set forth herein.

NOW THEREFORE, in consideration of the premises and the mutual covenants and
agreements herein contained, the parties hereto covenant and agree as follows:

      1.    From and after December 1, 2005 (the "Effective Date"), the
            Executive shall serve as the CMO of the Company and of the Parent
            Company, and perform all duties of a CMO for the Company and the
            Parent Company.

      2.    The Executive's gross monthly Salary for performing the duties of
            CMO for the Company and the Parent Company shall be US$ 8,000. To
            prevent any doubt, the Executive shall not be entitled to any
            additional compensation for duties performed on behalf of the Parent
            Company.

      3.    Any provision of the Agreement not specifically amended herein shall
            remain unaffected in effect and in force, mutatis mutandis.

IN WITNESS WHEREOF the parties hereto have executed this Amendment, effective as
of the date first written above.

ORIENS LIFE SCIENCES (ISRAEL) LTD.              EXECUTIVE

Per: /s/ Amnon Presler                          /s/ Shay Goldstein
     -----------------------                    ------------------
Name: Amnon Presler                             Shay Goldstein
Title: Chief Executive Officer

                                      -6-EXHIBIT 10.8

                        AMENDMENT TO EMPLOYMENT AGREEMENT

THIS AMENDMENT is entered into as of this 7 day of December, 2005, by and
between Oriens Life Sciences (Israel) Ltd., a private company duly registered in
Israel (the "Company"), and Ms. Tamar Tzaban-Nahomov (the "Executive").

WHEREAS the Executive currently serves in the role of Chief Financial Officer
("CFO") of the Company, pursuant to an Employment Agreement dated October 30,
2005 (the "Agreement"; all capitalized terms used and not otherwise defined
herein shall have the meaning ascribed to them in the Agreement); and

WHEREAS the Company and the Executive both wish to continue the Executive's
employment as CFO of the Company, under the terms and conditions set forth
herein.

NOW THEREFORE, in consideration of the premises and the mutual covenants and
agreements herein contained, the parties hereto covenant and agree as follows:

      1.    The Executive shall continue to serve as the CFO of the Company and
            of the Parent Company, and perform all duties of a CFO for the
            Company and the Parent Company.

      2.    From and after December 1, 2005 (the "Effective Date"), the
            Executive's gross monthly Salary for performing the duties of CFO
            for the Company and the Parent Company shall be US$ 8,000. To
            prevent any doubt, the Executive shall not be entitled to any
            additional compensation for duties performed on behalf of the Parent
            Company.

      3.    Any provision of the Agreement not specifically amended herein shall
            remain unaffected in effect and in force, mutatis mutandis.

IN WITNESS WHEREOF the parties hereto have executed this Amendment, effective as
of the date first written above.

ORIENS LIFE SCIENCES (ISRAEL) LTD.              EXECUTIVE

Per: Amnon Presler                              /s/ Tamar Tzaban-Nahomov
     ------------------------------             ------------------------
                                                Tamar Tzaban-Nahomov
Name: Amnon Presler
      -----------------------------

Title: Chief Executive Officer
       ----------------------------

                                      -7-EXHIBIT 10.9

                              EMPLOYMENT AGREEMENT

THIS AGREEMENT made this day, December 7, 2005.

BETWEEN:

      Oriens Life Sciences (Israel) Ltd., a company duly registered in Israel

      with an address of 23 Aminadav St., Tel Aviv, Israel

      (the "Company")

AND:

      Amnon Presler, an individual currently residing at

      74 Asher Street, Raanana 43553

      (the "Executive")

WHEREAS:

A. The Company has agreed to engage the Executive to serve in the role of the
Chief Executive Officer of the Company.

B. The Executive and the Company wish to formally record the terms and
conditions upon which the Executive will be employed by the Company and that
each of the Company and the Executive have agreed to the terms and conditions
set forth in this Agreement, as evidenced by their execution hereof.

NOW THEREFORE THIS AGREEMENT WITNESSES that in consideration of the premises and
the mutual covenants and agreements herein contained, the parties hereto
covenant and agree as follows:

                                    ARTICLE 1
                              CONTRACT FOR SERVICES

1.1   Engagement of Executive. The Executive shall serve as the CEO of the
      Company and shall perform his duties hereunder at the Company's facilities
      in Israel; however, the Executive acknowledges and agrees that the
      performance of his duties hereunder may require significant domestic and
      international travel.

1.2   Further Engagement of Executive. In addition, the Executive is employed as
      the CEO of the Company's parent company, SafeTek International Inc. (the
      "Parent Company"), without being entitled to any compensation other than
      the salary and additional compensation to which he is entitled pursuant to
      this Agreement.

<PAGE>

1.3   Term. The term of employment under this Agreement shall commence on
      December 1st. 2005 and shall continue until terminated by either party as
      provided herein (the "Term").

1.4   Exclusive Service. The Executive agrees to faithfully, honestly and
      diligently serve the Company and to devote the Executive's time, attention
      and best efforts to further the business and interests of the Company
      during the period of this Agreement to the exclusion of all other
      employment unless specifically authorized by the Company.

1.5   Duties. The Executive's services hereunder shall be provided on the basis
      of the following terms and conditions:

      (a)   reporting directly to the Board of Directors of the Company, the
            Executive shall serve as the CEO of the Company;

      (b)   the Executive shall be responsible for setting the overall corporate
            direction for the Company, including establishing and maintaining
            budgets for the Company and ensuring the Company has adequate
            capital for its operations, marketing and general corporate
            activities, all subject to any applicable law and to instructions
            provided by the Board of Directors of the Company from time to time;

      (c)   the Executive shall faithfully, honestly and diligently serve the
            Company and cooperate with the Company and utilize maximum
            professional skill and care to ensure that all services rendered
            hereunder are to the satisfaction of the Company, acting reasonably,
            and the Executive shall provide any other services not specifically
            mentioned herein, but which by reason of the Executive's capability
            the Executive knows or ought to know to be necessary to ensure that
            the best interests of the Company are maintained;

      (d)   the Executive shall assume, obey, implement and execute such duties,
            directions, responsibilities, procedures, policies and lawful orders
            as may be determined or given from time to time by the Company; and

      (e)   the Executive shall report the results of his duties hereunder to
            the Company as it may request from time to time.

                                    ARTICLE 2
                                  COMPENSATION

      Salary.

      (a)   For services rendered by the Executive during the Term, the
            Executive shall be paid throughout the Term a gross monthly salary,
            payable within 10 days after the end of each month (the "Salary").
            During the first two months in which the Executive receives a
            Salary, the Salary shall be US$ 7,500, and thereafter the Salary
            shall be US$ 8,500.

      (b)   The Salary shall be paid in NIS translated pursuant to the official
            representative rate of exchange of the US$ as published by the Bank
            of Israel on the payment date. Any deductions required to be made by
            the Company and submitted to relevant tax or other authorities will
            be deducted at source.

<PAGE>

      (c)   The Executive's Assignment is included among the positions of
            management or those requiring a special degree of personal trust,
            and the Company is not able to supervise the number of working hours
            of the Executive; therefore the provisions of the Israel Hours of
            Work and Rest Law - 1951, will not apply to the Executive and he
            will not be entitled to any additional remuneration whatsoever for
            his work with the exception of that specifically set out in this
            Agreement.

2.2   Bonus. In addition, if the aggregate investments made in the Company
      and/or the Parent Company after the date hereof exceed an amount of US$
      4,000,000, then the Executive shall be entitled to a bonus in the amount
      of US$ 8,500.

2.3   Options. The Executive shall be entitled to participate in the employee
      stock option plan to be adopted by the Parent Company (the "ESOP"), to an
      extent determined at the sole discretion of the Parent Company's Board of
      Directors, and only following and pending the adoption of the ESOP by the
      Parent Company.

2.4   Expenses. The Executive will be reimbursed by the Company for all
      reasonable business expenses incurred by the Executive in connection with
      his duties within previously approved budgets upon submission of a monthly
      statement of expenses. This includes, but not only, full use of cellular
      phone, use of one dedicated telephone/data line at home, daily newspaper,
      payments of expenses incurred when traveling abroad, per diem payments for
      travel abroad according to the rules set forth by the Israeli Tax
      Authorities and others. The Executive shall bear any tax payments
      resulting from the aforesaid, to the extant applicable.

2.5   Company Vehicle. The Executive shall be entitled to the use of a vehicle,
      as shall be determined by the Company, for which the Company shall incur
      all reasonable expenses associated therewith, but excluding personal
      traffic fines and the like. The use of such car shall be subject to the
      Company's instructions, as may be amended from time to time. The Executive
      shall bear any tax payments resulting from the aforesaid, to the extent
      applicable.

2.6   Vacation; Recreation Pay. The Executive shall be entitled to cumulative
      paid vacations of 24 days per year. In addition, Executive shall be
      entitled to sick leave and Recreation Pay according to applicable law.
      Executive shall be entitled to cash redemption of vested vacation upon
      termination of this agreement, with or without cause, according to Israeli
      Labor Law and practice.

2.7   Deductions. The Executive acknowledges that all payments by the Company in
      respect of the services provided by the Executive shall be net of all
      amounts which the Company as employer is required to deduct or withhold
      from Salary or other payments to an executive in accordance with statutory
      requirements (including, without limitation, income tax, employee
      contributions and unemployment insurance contributions).

<PAGE>

                                    ARTICLE 3
                          SOCIAL INSURANCE AND BENEFITS

3.1   Managers Insurance. The Company shall insure Executive under an accepted
      "Manager's Insurance Scheme", which in each case shall provide insurance
      in the event of illness or disability (hereinafter referred to as the
      "Managers Insurance") as follows: (i) the Company shall pay an amount
      equal up to 7.5% of Executive's Salary towards the Managers Insurance for
      Executive's benefit and Disability Insurance and shall deduct 5% from
      Executive's Salary and pay such amount towards the Managers Insurance for
      Executive's benefit (the various components of the Managers Insurance
      shall be fixed at the discretion of Executive); and (ii) the Company shall
      pay an amount equal to 8 1/3% of Executive's Salary towards a fund for
      severance compensation which shall be payable to Executive upon severance,
      subject to provisions of Section 3.3 herein. The aforementioned
      allocations shall be in lieu of severance pay according to the Israeli
      Severance Pay Law - 1963.

3.2   Keren Hishtalmut Fund. The Company and Executive shall open and maintain a
      Keren Hishtalmut Fund. The Company shall contribute to such Fund an amount
      equal to 7-1/2% of each monthly Salary payment, and Executive shall
      contribute to such Fund an amount of up to 2-1/2% of each monthly Salary
      payment. Executive hereby instructs the Company to transfer to such Fund
      the amount of Executive's and the Company's contribution from each monthly
      Salary payment. Notwithstanding the above, if the amounts to be
      contributed to the Keren Hishtalmut Fund will exceed the amount exempt
      from tax pursuant to the applicable tax regulations, any amount so
      exceeding shall not be transferred to such Fund but shall be added to the
      Salary.

3.3   Effect of Termination. Upon termination of this Agreement by either party,
      other than in circumstances constituting Cause (as defined below), the
      Company shall assign and transfer to the Executive, after Executive has
      met all of Executive's obligations hereunder in connection with such
      termination of employment, the ownership in the aforesaid Manager's
      Insurance and Keren Hishtalmut Fund. In the event that this Agreement is
      terminated in circumstances constituting Cause, the Company, in its
      absolute discretion, may retain its payments to such funds and release to
      the Executive only those sums contributed by Executive to such funds.

3.4   Liability Insurance Indemnification. Within a reasonable period of time
      following the signing of this agreement, the Company shall provide the
      Executive with coverage under a standard directors' and officers'
      liability insurance policy, at the Company's expense. In addition, the
      Executive shall be granted indemnification by the Parent Company in
      connection with his position therein.

<PAGE>

                                    ARTICLE 4
                                 CONFIDENTIALITY

4.1   Maintenance of Confidential Information. The Executive acknowledges that
      in the course of employment hereunder the Executive will, either directly
      or indirectly, have access to and be entrusted with information (whether
      oral, written or by inspection) relating to the Company or its Parent
      Company or their respective affiliates, associates or customers (the
      "Confidential Information"). For the purposes of this Agreement,
      "Confidential Information" includes, without limitation, any and all
      Developments (as defined herein), trade secrets, inventions, innovations,
      techniques, processes, formulas, drawings, designs, products, systems,
      creations, improvements, documentation, data, specifications, technical
      reports, customer lists, supplier lists, distributor lists, distribution
      channels and methods, retailer lists, reseller lists, employee
      information, financial information, sales or marketing plans, competitive
      analysis reports and any other thing or information whatsoever, whether
      copyrightable or uncopyrightable or patentable or unpatentable. The
      Executive acknowledges that the Confidential Information constitutes a
      proprietary right, which the Company is entitled to protect. Accordingly
      the Executive covenants and agrees that during the Term and thereafter
      until such time as all the Confidential Information becomes publicly known
      and made generally available through no action or inaction of the
      Executive, the Executive will keep in strict confidence the Confidential
      Information and shall not, without prior written consent of the Company,
      disclose, use or otherwise disseminate the Confidential Information,
      directly or indirectly, to any third party.

4.2   Exceptions. The general prohibition contained in Section 4.1 against the
      unauthorized disclosure, use or dissemination of the Confidential
      Information shall not apply in respect of any Confidential Information
      that:

      (a)   is available to the public generally in the form disclosed;

      (b)   becomes part of the public domain through no fault of the Executive;

      (c)   is already in the lawful possession of the Executive at the time of
            receipt of the Confidential Information; or

      (d)   is compelled by applicable law to be disclosed, provided that the
            Executive gives the Company prompt written notice of such
            requirement prior to such disclosure and provides assistance in
            obtaining an order protecting the Confidential Information from
            public disclosure.

4.3   Developments. Any information, technology, technical data or any other
      thing or documentation whatsoever which the Executive, either by himself
      or in conjunction with any third party, has conceived, made, developed,
      acquired or acquired knowledge of during the Executive's employment with
      the Company or which the Executive, either by himself or in conjunction
      with any third party, shall conceive, make, develop, acquire or acquire
      knowledge of (collectively the "Developments") during the Term or at any
      time thereafter during which the Executive is employed by the Company that
      is related to conducting research and clinical study shall automatically

<PAGE>

      form part of the Confidential Information and shall become and remain the
      sole and exclusive property of the Company. Accordingly, the Executive
      does hereby irrevocably, exclusively and absolutely assign, transfer and
      convey to the Company in perpetuity all worldwide right, title and
      interest in and to any and all Developments and other rights of whatsoever
      nature and kind in or arising from or pertaining to all such Developments
      created or produced by the Executive during the course of performing this
      Agreement, including, without limitation, the right to effect any
      registration in the world to protect the foregoing rights. The Company
      shall have the sole, absolute and unlimited right throughout the world,
      therefore, to protect the Developments by patent, copyright, industrial
      design, trademark or otherwise and to make, have made, use, reconstruct,
      repair, modify, reproduce, publish, distribute and sell the Developments,
      in whole or in part, or combine the Developments with any other matter, or
      not use the Developments at all, as the Company sees fit.

4.4   Protection of Developments. The Executive does hereby agree that, both
      before and after the termination of this Agreement, the Executive shall
      perform such further acts and execute and deliver such further
      instruments, writings, documents and assurances (including, without
      limitation, specific assignments and other documentation which may be
      required anywhere in the world to register evidence of ownership of the
      rights assigned pursuant hereto) as the Company shall reasonably require
      in order to give full effect to the true intent and purpose of the
      assignment made under Section 4.3 hereof. If the Company is for any reason
      unable, after reasonable effort, to secure execution by the Executive on
      documents needed to effect any registration or to apply for or prosecute
      any right or protection relating to the Developments, the Executive hereby
      designates and appoints the Company and its duly authorized officers and
      agents as the Executive's agent and attorney to act for and in the
      Executive's behalf and stead to execute and file any such document and do
      all other lawfully permitted acts necessary or advisable in the opinion of
      the Company to effect such registration or to apply for or prosecute such
      right or protection, with the same legal force and effect as if executed
      by the Executive.

4.5   Fiduciary Obligation. The Executive declares that the Executive's
      relationship to the Company is that of fiduciary, and the Executive agrees
      to act towards the Company and otherwise behave as a fiduciary of the
      Company.

4.6   Remedies. The parties to this Agreement recognize that any violation or
      threatened violation by the Executive of any of the provisions contained
      in this Article 4. will result in immediate and irreparable damage to the
      Company and that the Company could not adequately be compensated for such
      damage by monetary award alone. Accordingly, the Executive agrees that in
      the event of any such violation or threatened violation, the Company
      shall, in addition to any other remedies available to the Company at law
      or in equity, be entitled as a matter of right to apply to such relief by
      way of restraining order, temporary or permanent injunction and to such
      other relief as any court of competent jurisdiction may deem just and
      proper.

<PAGE>

4.7   Reasonable Restrictions. The Executive agrees that all restrictions in
      this Article 4 are reasonable and valid, and all defenses to the strict
      enforcement thereof by the Company are hereby waived by the Executive.

                                    ARTICLE 5
                                 NON-COMPETITION

5.1   Non Competition. Executive agrees and undertakes that he will not, so long
      as he is employed by the Company and for a period of 12 months following
      termination of his employment for whatever reason, directly or indirectly,
      as owner, partner, joint venture, stockholder, employee, broker, agent,
      principal, corporate officer, director, licensor or in any other capacity
      whatever engage in, become financially interested in, be employed by, or
      have any connection with any business or venture that competes with the
      Company's business, including any business which, when this Agreement
      terminates, the Company contemplates in good faith to be materially
      engaged in within 12 months thereafter, provided that the Company has
      taken demonstrable actions to promote such engagement or that the
      Company's Board of Directors has adopted a resolution authorizing such
      actions prior to the date of termination; provided, however, that
      Executive may own securities of any corporation which is engaged in such
      business and is publicly owned and traded but in an amount not to exceed
      at any one time one percent (1%) of any class of stock or securities of
      such company, so long as he has no active role in the publicly owned and
      traded company as director, employee, consultant or otherwise.

5.2   No Solicitation. Executive agrees and undertakes that during the period of
      his employment and for a period of 12 months following termination, he
      will not, directly or indirectly, including personally or in any business
      in which he is an officer, director or shareholder, for any purpose or in
      any place, employ any person (as an employee or consultant) employed by
      the Company at such time or during the preceding twelve months, unless
      such person has been terminated by the Company, provided however, that
      such person who is terminated by the Company may be employed by Executive
      as described above only after the expiration of twelve months after the
      effective date of such termination.

                                    ARTICLE 6
                                   TERMINATION

6.1   Termination For Cause or Disability. This Agreement may be terminated at
      any time by the Company without notice, for Cause or in the event of the
      Disability of Executive.

      For the purposes of this Agreement, "Cause" also means that the Executive
      shall have:

      (a)   committed an intentional act of fraud, embezzlement or theft in
            connection with the Executive's duties or in the course of the
            Executive's employment with the Company;

<PAGE>

      (b)   intentionally and wrongfully damaged property of the Company, or any
            of its respective affiliates, associates or customers;

      (c)   intentionally or wrongfully disclosed any of the Confidential
            Information;

      (d)   made material personal benefit at the expense of the Company without
            the prior written consent of the management of the Company;

      (e)   accepted shares or options or any other gifts or benefits from a
            vendor without the prior written consent of the management of the
            Company;

      (f)   fundamentally breached any of the Executive's material covenants
            contained in this Agreement; or

      (g)   willfully and persistently, without reasonable justification, failed
            or refused to follow the lawful and proper directives of the Company
            specifying in reasonable detail the alleged failure or refusal and
            after a reasonable opportunity for the Executive to cure the alleged
            failure or refusal.

      For the purposes of this Agreement, an act or omission on the part of the
      Executive shall not be deemed "intentional," if it was due to an error in
      judgment or negligence, but shall be deemed "intentional" if done by the
      Executive not in good faith and without reasonable belief that the act or
      omission was in the best interests of the Company, or its respective
      affiliates, associates or customers.

      For the purposes of this Agreement, "Disability" shall mean any physical
      or mental illness or injury as a result of which Executive remains absent
      from work for a period of six (6) successive months, or an aggregate of
      six (6) months in any twelve (12) month period. Disability shall occur
      upon the end of such six-month period.

6.2   Severance for Termination With Cause. If the Company terminates the
      Executive's employment for Cause, then the Company will not be obligated
      to pay the Executive any severance payments or provide any notice
      whatsoever to the Executive.

6.3   Termination Without Cause. Either the Executive or the Company may
      terminate the Executive's employment without Cause, for any reason
      whatsoever, with 30 days notice within the first year of the Executive's
      engagement and with 90 days prior written notice thereafter.

6.4   The Notice Period.

      (a)   During the period following the notice of termination (the "Notice
            Period"), Executive shall cooperate with the Company and use his
            best efforts to assist the integration into the Company's
            organization of the person or persons who will assume Executive's
            responsibilities.

      (b)   This Agreement shall remain in full force and effect until the end
            of the Notice Period and there shall be no change in Executive's
            compensation terms or any of his obligations hereunder during such
            Notice period.

<PAGE>

      (c)   Notwithstanding sub-section (b) above, during the Notice Period the
            Company may, at its discretion, relieve Executive of his position,
            upon which Executive shall leave the Company. Such actions shall not
            derogate in any way or manner whatsoever from Executive's rights to
            receive the Salary until the end of the Notice period.

6.5   Limitation of Damages. It is agreed that in the event of termination of
      employment, neither the Company, nor the Executive shall be entitled to
      any notice, or payment in excess of that specified in this Article 6.

6.6   Return of Materials. Within three (3) days of any termination of
      employment hereunder, or upon any request by the Company at any time, the
      Executive will return or cause to be returned any and all Confidential
      Information and other assets of the Company (including all originals and
      copies thereof), which "assets" include, without limitation, hardware,
      software, keys, security cards and backup tapes that were provided to the
      Executive either for the purpose of performing the employment services
      hereunder or for any other reason. The Executive acknowledges that the
      Confidential Information and the assets are proprietary to the Company,
      and the Executive agrees to return them to the Company in the same
      condition as the Executive received such Confidential Information and
      assets.

6.7   Effect of Termination. Articles 3.3, 3.4, 4, 5 and 6.6 hereto shall remain
      in full force and effect after termination of this Agreement, for any
      reason whatsoever.

                                    ARTICLE 7
                             MUTUAL REPRESENTATIONS

7.1   Executive represents and warrants to the Company that the execution and
      delivery of this Agreement and the fulfillment of the terms hereof (i)
      will not constitute a default under or conflict with any agreement or
      other instrument to which he is a party or by which he is bound, and (ii)
      do not require the consent of any person or entity.

7.2   The Company represents and warrants to Executive that this Agreement has
      been duly authorized, executed and delivered by the Company and that the
      fulfillment of the terms hereof (i) will not constitute a default under or
      conflict with any agreement of other instrument to which it is a party or
      by which it is bound, and (ii) do not require the consent of any person of
      entity.

7.3   Each party hereto warrants and represents to the other that this Agreement
      constitutes the valid and binding obligation of such party enforceable
      against such party in accordance with its terms subject to applicable
      bankruptcy, insolvency, moratorium and similar laws affecting creditors'
      rights generally, and subject, as to enforceability, to general principles
      of equity (regardless if enforcement is sought in proceeding in equity or
      at law).

<PAGE>

                                    ARTICLE 8
                                     NOTICES

8.1   Notices. All notices required or allowed to be given under this Agreement
      shall be made either personally by delivery to or by facsimile
      transmission to the address as hereinafter set forth or to such other
      address as may be designated from time to time by such party in writing:

      (a)   in the case of the Company, to:

                  Oriens Life Sciences (Israel), Ltd.
                  23 Aminadav St., Tel Aviv, Israel
                  Attn: _______
                  Fax: 972-3-561-3465

            with a copy to

                  Ori Rosen, Adv.
                  Ori Rosen & Co. Law Offices, 1 Azrieli Center (Round Building)
                  Tel Aviv 67021, Israel
                  Fax: 972-3-607-4701
                  Email: ori@rosenlaw.co.il

      (b)   and in the case of the Executive, to the Executive's last residence
            address known to the Company.

8.2   Change of Address. Any party may, from time to time, change its address
      for service hereunder by written notice to the other party in the manner
      aforesaid.

                                    ARTICLE 9
                                     GENERAL

9.1   Entire Agreement. As of from the date hereof, any and all previous
      agreements, written or oral between the parties hereto or on their behalf
      relating to the employment of the Executive by the Company are null and
      void. The parties hereto agree that they have expressed herein their
      entire understanding and agreement concerning the subject matter of this
      Agreement and it is expressly agreed that no implied covenant, condition,
      term or reservation or prior representation or warranty shall be read into
      this Agreement relating to or concerning the subject matter hereof or any
      matter or operation provided for herein.

9.2   Personal Agreement. The provisions of this Agreement are in lieu of the
      provisions of any collective bargaining agreement, and therefore, no
      collective bargaining agreement shall apply with respect to the
      relationship between the parties hereto (subject to the applicable
      provisions of law).

<PAGE>

9.3   Further Assurances. Each party hereto will promptly and duly execute and
      deliver to the other party such further documents and assurances and take
      such further action as such other party may from time to time reasonably
      request in order to more effectively carry out the intent and purpose of
      this Agreement and to establish and protect the rights and remedies
      created or intended to be created hereby.

9.4   Waiver. No provision hereof shall be deemed waived and no breach excused,
      unless such waiver or consent excusing the breach is made in writing and
      signed by the party to be charged with such waiver or consent. A waiver by
      a party of any provision of this Agreement shall not be construed as a
      waiver of a further breach of the same provision.

9.5   Amendments in Writing. No amendment, modification or rescission of this
      Agreement shall be effective unless set forth in writing and signed by the
      parties hereto.

9.6   Assignment. Except as herein expressly provided, the respective rights and
      obligations of the Executive and the Company under this Agreement shall
      not be assignable by either party without the written consent of the other
      party and shall, subject to the foregoing, enure to the benefit of and be
      binding upon the Executive and the Company and their permitted successors
      or assigns. Nothing herein expressed or implied is intended to confer on
      any person other than the parties hereto any rights, remedies, obligations
      or liabilities under or by reason of this Agreement.

9.7   Severability. In the event that any provision contained in this Agreement
      shall be declared invalid, illegal or unenforceable by a court or other
      lawful authority of competent jurisdiction, such provision shall be deemed
      not to affect or impair the validity or enforceability of any other
      provision of this Agreement, which shall continue to have full force and
      effect.

9.8   Headings. The headings in this Agreement are inserted for convenience of
      reference only and shall not affect the construction or interpretation of
      this Agreement.

9.9   Number and Gender. Wherever the singular or masculine or neuter is used in
      this Agreement, the same shall be construed as meaning the plural or
      feminine or a body politic or corporate and vice versa where the context
      so requires.

9.10  Time. Time shall be of the essence of this Agreement.

9.11  Governing Law. This Agreement shall be construed and interpreted in
      accordance with the laws of the state of Israel applicable therein, and
      each of the parties hereto expressly attorns to the jurisdiction of the
      courts of the state of Israel. The sole and exclusive place of
      jurisdiction in any matter arising out of or in connection with this
      Agreement shall be the applicable Tel-Aviv court.

<PAGE>

9.12  Enurement. This Agreement is intended to bind and enure to the benefit of
      the Company, its successors and assigns, and the Executive and the
      personal legal representatives of the Executive.

                [Remainder of this page left intentionally blank]

<PAGE>

IN WITNESS WHEREOF the parties hereto have executed this Agreement effective as
of the date and year first above written.

Oriens Life Sciences (Israel) Ltd.              EXECUTIVE

Per: /s/ Shay Goldstein                         /s/ Amnon Presler
     ------------------------------             ------------------------------
                                                Amnon Presler
Name: /s/ Shay Goldstein
      -----------------------------

Title: Chief Executive Officer
       ----------------------------

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00094-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00094-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00094-of-00352.parquet"}]]